“…BALF cell profile data also suggest that challenge with warm, wet air [10,11,13], and pretreatment with β-agonists [14,15], attenuate AIB and significantly protect the canine mucosa from airway desiccation, when compared to untreated dry air challenged segments. In addition to β-agonists [14][15][16], methylxanthines [16,17], muscarinic receptor antagonists [13,18], cyclo-oxygenase inhibitors [11,13,19], leukotriene antagonists [20,21], and airway cooling [6][7][8][9] reduce or abolish AIB in canine peripheral airways and individuals with asthma.…”